摘要
目的观察沙利度胺联合卡培他滨对晚期乳腺癌的疗效及毒性。方法46例Ⅲ～Ⅳ晚期乳腺癌随机分为卡培他滨联合沙利度胺组(A组)和卡培他滨组(B组),A组23例接受卡培他滨2500mg/m2,分早晚两次餐后30min温开水送服,第1～14天,间隔7天,沙利度胺100mg,口服,第1～14天,21天为1周期,化疗4个周期;B组23例不服用沙利度胺。结果A组:CR3例,PR9例,SD8例,PD3例,有效率52.2%,疾病控制率为87%;B组:CR1例,PR4例,SD13例,PD5例,有效率21.7%,疾病控制率为73.9%。结论卡培他滨联合沙利度胺治疗晚期乳腺癌疗效较好,不良反应轻,患者可耐受。
Objective To observe the efficiency and toxicity of capecitabine combined with thalidomide in the treatment of advanced breast cancer. Methods Total 46 patients were randomized into eapecitabine plus thailidomide group （group A） and eapecitabine group（group B）. grpup A ：twenty -three patients were treated with capecitabine 2500mg/m2, day1 - 14. thalidomide 100mg/m2 , dayl 14;group B：twenty -three had not thalidomide. 1 cycle was 21 days,treated 4 cycles. Results 3 of 23 assessable patients in group A achieved complete response （CR） ; 1 patient in group B. 9 patients in group A had partial response（PR） ;4 patients in group B. 8 ones in group A had stable disease（SD） ; 13 ones in group B. 3 patients in group A had progressive disease（PD） ;5 ones in group B. The respone rate in group A was 52.2% ;21.7% in group B. Conclusion Capecitabine combined with thalido- mide was an effective regimen with tolerable toxicity in the treatment of advanced breast cancer.
出处
《医药论坛杂志》
2009年第24期37-38,共2页
Journal of Medical Forum
关键词
晚期乳腺癌
卡培他滨
沙利度胺
Advanced breast cancer
Capecitabine
Thalidomide
